Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.33696/cancerimmunol.4.062
OGR1-a Novel Modulator Target of Tumor Immunotherapy
Guoxin Zhang1,2,3, Ran Gao1,2,3,*
- 1National Human Diseases Animal Model Resource Center, The Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
- 2NHC Key Laboratory of Human Disease Comparative Medicine, Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing, China
- 3Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Beijing, Chi
Corresponding Author
Ran Gao, gaoran@cnilas.org
Received Date: February 23, 2022
Accepted Date: March 29, 2022
Zhang G, Gao R. OGR1-a Novel Modulator Target of Tumor Immunotherapy. J Cancer Immunol. 2022;4(1):30-32.
Copyright: © 2022 Zhang G, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Impact of Cisplatin Dosing Regimens on Mammary Tumor Growth in an Animal Model
In a recent paper, we introduced a variant of the classical Simeoni tumor growth model, and illustrated its value in assessing tumor growth in a reproducible mouse model for mammary tumors. Our modification consisted of incorporating delay differential equations in the mathematical formulation of the Simeoni model, to represent the delay in drug action often observed under chemotherapeutic or immunotherapeutic regimens.
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
The Effect of Glucocorticoids on Angiogenesis in the Treatment of Solid Tumors
Glucocorticoids (GCs) are defined by their role in maintaining glucose homeostasis and natural GCs are a class of corticosteroids secreted by the adrenal cortex. Cortisol is the most important natural GC in humans. Cellular cortisol levels are regulated by the tissue-specific metabolic enzymes 11β-hydroxysteroid dehydrogenase 1 and 2 (11β-HSD 1 and 2); 11β-HSD 1 converts inactive cortisone to active cortisol, while 11β-HSD 2 has the opposite function.
Role of the Gut Microbiome in the Modulation of Cancer Immunotherapy Response
The gut microbiome or gut flora is a vast community of microorganisms such as bacteria, viruses, protozoa, and fungi that inhabit the digestive tract of the human and other animals [1,2]. In the human body, bacterial species colonize into the oral cavity, skin, vagina, and placenta, however, the largest population of microorganisms resides in the intestine.